Table 1 presents data on the association between plasma ctDNA/cfDNA EGFR mutations and the efficacy and prognosis of targeted therapy in NSCLC patients [28,30,31,32,33,34,35,45,46,47,48,49,50,51,52,53,54,55,56,57,58]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.